NTRK1 and acute myeloid leukemia: In AML, the RAS pathway is activated both by mutations occurring in RAS as well mutations and/or overexpression of upstream receptor tyrosine kinases such as FLT3. RAS inhibitors have had an underwhelming impact on AML.